Oscar G. Bukstein, MD, MPH
Associate Director, Faculty Development, Department of Psychiatry and Behavioral Sciences
Professor of Psychiatry, Harvard Medical School
Image
Oscar G. Bukstein, MD, MPH
Associate Director, Faculty Development, Department of Psychiatry and Behavioral Sciences
Professor of Psychiatry, Harvard Medical School
Medical Services
Languages
English
Certifications
American Board of Psychiatry and Neurology (Psychiatry)
American Board of Psychiatry and Neurology (Child and Adolescent Psychiatry)
Publications
Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. View Abstract
Screening for Adolescent Depression and Suicide Risk. View Abstract
Clinical Update: Collaborative Mental Health Care for Children and Adolescents in Pediatric Primary Care. View Abstract
Clinical Update: Child and Adolescent Behavioral Health Care in Community Systems of Care. View Abstract
Adolescent Substance Use Disorders. View Abstract
Measurement-Based Care in the Treatment of Adolescents with Substance Use Disorders. View Abstract
Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. View Abstract
Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. View Abstract
Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation. View Abstract
Practice Parameter for the Assessment and Treatment of Psychiatric Disorders in Children and Adolescents With Intellectual Disability (Intellectual Developmental Disorder). View Abstract
The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. View Abstract
The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. View Abstract
Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. View Abstract
Forward to the Future: Clinical Updates and Clinical Practice Guidelines. View Abstract
Challenges and Gaps in Understanding Substance Use Problems in Transitional Age Youth. View Abstract
Comparing treatments for children with ADHD and word reading difficulties: A randomized clinical trial. View Abstract
The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. View Abstract
The Effectiveness of Short- and Long-Acting Stimulant Medications for Adolescents With ADHD in a Naturalistic Secondary School Setting. View Abstract
Acute Effects of MPH on the Parent-Teen Interactions of Adolescents With ADHD. View Abstract
Attributions and Perception of Methylphenidate Effects in Adolescents With ADHD. View Abstract
Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. View Abstract
Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. View Abstract
Substance Use Disorders Among Adolescents. View Abstract
Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. View Abstract
Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. View Abstract
Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. View Abstract
Factor Validity of a Proactive and Reactive Aggression Rating Scale. View Abstract
Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. View Abstract
Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. View Abstract
Treatment development and feasibility study of family-focused treatment for adolescents with bipolar disorder and comorbid substance use disorders. View Abstract
Evaluation of a booster intervention three years after acute treatment for early-onset disruptive behavior disorders. View Abstract
What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? View Abstract
Personality-targeted interventions delivered by teachers may be effective at reducing alcohol use. View Abstract
Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. View Abstract
Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. View Abstract
Taking note of over-the-counter remedies for adolescents with cannabis dependence. View Abstract
Attention deficit hyperactivity disorder and substance use disorders. View Abstract
Predicting Treatment Response for Oppositional Defiant and Conduct Disorder Using Pre-treatment Adrenal and Gonadal Hormones. View Abstract
Practice parameter for child and adolescent forensic evaluations. View Abstract
A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. View Abstract
The treatment of severe child aggression (TOSCA) study: Design challenges. View Abstract
Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. View Abstract
Medication refusal in children with oppositional defiant disorder or conduct disorder and comorbid attention-deficit/hyperactivity disorder: medication history and clinical correlates. View Abstract
Influence of treatment for disruptive behavior disorders on adrenal and gonadal hormones in youth. View Abstract
Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review. View Abstract
Management of the adolescent with substance use disorders and comorbid psychopathology. View Abstract
Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. View Abstract
Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. View Abstract
Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. View Abstract
Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? View Abstract
Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. View Abstract
The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. View Abstract
Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. View Abstract
Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. View Abstract
Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. View Abstract
Substance use disorders and ADHD. View Abstract
Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. View Abstract
Transdermal methylphenidate system: old wine in a new bottle. View Abstract
Brief screens for detecting alcohol use disorder among 18-20 year old young adults in emergency departments: Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale. View Abstract
Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. View Abstract
Practice parameter for the psychiatric assessment and management of physically ill children and adolescents. View Abstract
Salivary gonadal and adrenal hormone differences in boys and girls with and without disruptive behavior disorders: Contextual variants. View Abstract
Evidence of developmental alterations in cortical and subcortical regions of children with attention-deficit/hyperactivity disorder: a multivoxel in vivo phosphorus 31 spectroscopy study. View Abstract
Substance use disorders in adolescents with attention-deficit/hyperactivity disorder. View Abstract
Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. View Abstract
Sexual orientation and adolescent substance use: a meta-analysis and methodological review. View Abstract
Attention deficit hyperactivity disorder and substance use disorders. View Abstract
A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. View Abstract
Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. View Abstract
Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. View Abstract
Substance abuse in patients with attention-deficit/hyperactivity disorder. View Abstract
Feasibility and preliminary efficacy of an after-school program for middle schoolers with ADHD: a randomized trial in a large public middle school. View Abstract
A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. View Abstract
Changes and challenges: managing ADHD in a fast-paced world. View Abstract
Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. View Abstract
AACAP 2005 Research Forum: speeding the adoption of evidence-based practice in pediatric psychiatry. View Abstract
Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. View Abstract
Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. View Abstract
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. View Abstract
Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders. View Abstract
Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. View Abstract
Clinical predictors of treatment in a population of adolescents with alcohol use disorders. View Abstract
Alcohol use disorder symptoms and risk-taking behavior as predictors of alcohol-related medical events among young adults treated in emergency departments. View Abstract
Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. View Abstract
Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. View Abstract
Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study. View Abstract
Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. View Abstract
Alcohol use disorder in adolescents. View Abstract
Treatment of co-occurring alcohol, drug, and psychiatric disorders. View Abstract
Practice parameter for use of electroconvulsive therapy with adolescents. View Abstract
Practice parameter for the assessment and treatment of children and adolescents with enuresis. View Abstract
Salient variables for treatment research of adolescent alcohol and other substance use disorders. View Abstract
Major depression associated with earlier alcohol relapse in treated teens with AUD. View Abstract
Satisfaction with treatment for attention-deficit/hyperactivity disorder. View Abstract
Interventions in suicidal alcoholics. View Abstract
Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. View Abstract
Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. View Abstract
Psychiatric disorders among older adolescents treated in emergency departments on weekends: a comparison with a matched community sample. View Abstract
Once-daily atomoxetine may reduce attention deficit hyperactivity disorder symptoms in children and adolescents. View Abstract
Alcohol and psychiatric comorbidity. View Abstract
Attention-deficit/hyperactivity disorder and conduct disorder symptomatology in adolescents with alcohol use disorder. View Abstract
Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. View Abstract
Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. View Abstract
Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment. View Abstract
Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. View Abstract
Summary of the practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions with special reference to seclusion and restraint. View Abstract
Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. View Abstract
Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. View Abstract
Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. View Abstract
Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. View Abstract
Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. View Abstract
Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. View Abstract
Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents. View Abstract
Disruptive behavior disorders and substance use disorders in adolescents. View Abstract
Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. View Abstract
Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. View Abstract
Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. View Abstract
Psychopathology in adolescent alcohol abuse and dependence. View Abstract
Practice parameters for the assessment and treatment of children and adolescents with substance use disorders. American Academy of Child and Adolescent Psychiatry. View Abstract
Gender and comorbid psychopathology in adolescents with alcohol dependence. View Abstract
Identifying anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. View Abstract
Self-reported health problems and physical symptomatology in adolescent alcohol abusers. View Abstract
Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. View Abstract
Cognitive distortions and adolescent affective disorder. Validity of the CNCEQ in an inpatient sample. Children's Negative Cognitive Error Questionnaire. View Abstract
Cognitive distortions and psychiatric diagnosis in dually diagnosed adolescents. View Abstract
Treatment of Adolescent Alcohol Abuse and Dependence. View Abstract
Risk factors for completed suicide among adolescents with a lifetime history of substance abuse: a case-control study. View Abstract
Drug abuse prevention for high-risk African American children and their families: a review and model program. View Abstract
Patterns of polydrug use in adolescent alcohol abusers. View Abstract
Social skills and depression in adolescent substance abusers. View Abstract
Patterns of affective comorbidity in a clinical population of dually diagnosed adolescent substance abusers. View Abstract
Comparison between treatment completers and noncompleters among dually diagnosed substance-abusing adolescents. View Abstract
Maltreatment in psychiatrically hospitalized dually diagnosed adolescent substance abusers. View Abstract
The Teen-Addiction Severity Index: rationale and reliability. View Abstract
Multivariate comparison of adolescent offspring of substance abuse parents: community and treatment samples. View Abstract
Drug abuse severity in adolescents is associated with magnitude of deviation in temperament traits. View Abstract
Reliability and validity of the structured interview for personality disorders in adolescents. View Abstract
Comorbidity of substance abuse and other psychiatric disorders in adolescents. View Abstract
Adolescent chemical use and dependence: current issues in epidemiology, treatment and prevention. View Abstract
Teen Addiction Severity Index (T-ASI): clinical and research implications: a preliminary report. View Abstract